Effect of ibopamine on peripheral haemodynamics

Longhini, C; Musacci, G. F.; Ansani, L; Toselli, Tiziano; Artioli, M; Bianco, Lucia Dal; Ghirardi, P

doi:10.1007/bf00542205

Cited by 16 publications

(14 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the effect on cardiac preload is less clear [4][5][6][7][8][9][10][11][12][13][14]. As measured by plethysmography, IBO may increase forearm blood volume in healthy volunteers and patients with CHF [15,16]. This may contradict volumetric studies in animals and man showing that dopamine tends to constrict peripheral veins [17,18]:…”

contrasting

confidence: 39%

Acute effect of ibopamine and isosorbide mononitrate on blood volume distribution in congestive heart failure

Holman

Groeneveld

Schneider

et al. 1994

Eur J Clin Pharmacol

View full text Add to dashboard Cite

In order to compare ibopamine (IBO), a dopamine congener, with isosorbide mononitrate (ISMN) and to study their interaction in effects on the capacitance vasculature in congestive heart failure (CHF), a prospective, randomized, placebo-controlled, double-blind clinical trial was performed in 32 patients with New York Heart Association class II-IV CHF, randomly assigned to receive single oral doses of placebo, 200 mg IBO, 20 mg ISMN, or both IBO and ISMN. After labelling of red cells with 99mTc, changes in regional radioactivity, indicative of changes in blood volume, were recorded using a gamma-camera before and at 30, 60 and 120 min after drug administration. At 30 and 60 min, arterial systolic and pulse pressures were higher with IBO than with ISMN and placebo (for pulse pressure by mean 13.7 mmHg, 95% confidence interval 4.5-23.0 mmHg, at 30 min), probably reflecting an IBO-induced rise in stroke volume at unchanged heart rate and mean arterial pressure. IBO did not change regional radioactivity except for a transient increase of 4.4% (0.5-7.6%) in the thorax at 30 min. This was attenuated by concomitant ISMN treatment since, starting at 30 min, the drug increased radioactivity in the legs, compared with patients not receiving the drug, by 8.0% (95% confidence interval 0.2-15.8%), leading to a fall in thoracic and left ventricular radioactivity at 30 min of 3.4% (0.3-7.0%) and 6.4% (0.8-11.9%), respectively, and a fall of 5.5% (0.5-10.5%) in hepatic radioactivity at 60 min.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

contrasting

confidence: 39%

Acute effect of ibopamine and isosorbide mononitrate on blood volume distribution in congestive heart failure

Holman

Groeneveld

Schneider

et al. 1994

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…The cardiac and peripheral vascular activity of ibopamine is complemented by its activity on the kidney Ghirardi et al, 1980;Longhini et al, 1983;Merlo et al, 1979;Stefoni et al, 1981;. This combined action on the myocardium, after-and pre-load, tends to improve cardiac performance and the haemodynamic pattern in CHF.…”

Section: Discussionmentioning

confidence: 99%

Acute haemodynamic effects of ibopamine in patients with severe congestive heart failure.

Ghirardi¹,

Brusoni²,

Mangiavacchi³

et al. 1985

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 Ten patients with congestive heart failure (CHF), in III and IV NYHA Class, were treated orally with a single dose of ibopamine ranging from 1.2-3.3 mg/kg, and were studied using the Swan-Ganz catheter and thermodilution technique. 2 Cardiac index (CI) and stroke volume index (SVI) were increased, and mean pulmonary pressure (PAP), systemic vascular resistances (SVR) were lowered. Ibopamine increased CI (+33%) and SVI (+26%), and decreased PAP (-17%) and SVR (-24%). All changes were statistically significant. The maximum haemodynamic effect occurred 180 min after ibopamine administration. Blood pressure and heart rate were unaffected. Tolerability was good. 3 This study shows that ibopamine when orally administered to human subjects improves cardiac performance and further investigations on its use as a therapeutic agent in the long term treatment of CHF are recommended.

show abstract

“…Mean of 6 subjects, b Plasma concentrations of free epinine (pmol/ml) after admin istration of a single oral dose of 100 mg ibopamine base. Mean of 6 subjects [from I], eral vasodilating action of ibopamine was also demonstrated by using a strain gauge Plethysmograph in healthy volunteers and in patients with congestive heart failure [5,6], Sulpiride, a specific dopaminergic antago nist, counteracted the activity of ibopamine.…”

Section: Acute Effects Of Ibopaminementioning

confidence: 99%

Ibopamine - How Should It Be Used?

Bussmann¹,

Wienhöfer²,

Frik³

1988

Cardiology

View full text Add to dashboard Cite

Ibopamine is an orally effective derivative of dopamine capable of eliciting peripheral and renal vasodilating activity and positive inotropic action. The compound is a prodrug which is enzymatically converted by plasma and peripheral tissues esterases to epinine (N-methyldopamine) which is the active drug. Effective plasma epinine levels are readily achieved, producing the hemodynamic action for 4-6 h. Acute and chronic studies demonstrated an improvement in cardiac output and a reduction in pre- and afterload.

show abstract

Effect of ibopamine on peripheral haemodynamics

Cited by 16 publications

References 6 publications

Acute effect of ibopamine and isosorbide mononitrate on blood volume distribution in congestive heart failure

Acute effect of ibopamine and isosorbide mononitrate on blood volume distribution in congestive heart failure

Acute haemodynamic effects of ibopamine in patients with severe congestive heart failure.

Ibopamine - How Should It Be Used?

Contact Info

Product

Resources

About